Perspectives in Breast Cancer:
The Growing Role of Taxanes
in the Adjuvant Setting
DATE: October 2003
Each year, more than 200,000 women in the United States undergo
treatment for breast cancer. While disease management had largely
focused on aggressive local surgery, current strategies are emphasizing
earlier systemic treatment. In the early 1990s, the taxanes were established
as active agents in metastatic breast cancer, and their role in this
area is evolving. This activity reviews data from the most mature
trials of taxanes in adjuvant chemotherapy.
This educational activity is intended for physicians, pharmacists,
and nurses involved in the management of patients with cancer.
At the completion of this activity, participants
should be able to:
- Review use
of taxanes in adjuvant setting
- Discuss data
from recent trials of dose-dense chemotherapy with taxanes
- Describe controversies
associated with dose-dense chemotherapy
the role of adjuvant chemotherapy with taxanes in patients with
AND CREDIT DESIGNATION
This activity has been planned and implemented in accordance with
the Essential Areas and policies of the Accreditation Council for
Continuing Medical Education through the joint sponsorship of the
Dannemiller Memorial Educational Foundation and the McMahon Publishing
Group. The Dannemiller Memorial Educational Foundation is accredited
by the ACCME to provide continuing medical education for physicians.
The Dannemiller Memorial Educational Foundation designates this educational
activity for a maximum of 1 category 1 credit toward the American
Medical Association Physicians Recognition Award. Each physician
should claim only those credits that he/she actually spent in the
The Dannemiller Memorial Educational Foundation is an approved provider
of the California Board of Registered Nursing. Provider approved by
the California Board of Registered Nursing, Provider Number 4229,
for 1 contact hour.
University is accredited by the American Council on Pharmaceutical
Education as a provider of continuing pharmaceutical education.
This is a continuing education activity of Purdue, an equal access/equal
opportunity university. To receive the 1 contact hour of continuing
education credit, pharmacists should complete the activity requirements
and evaluation at the conclusion of the monograph. Approval is
valid from the initial release date of October 23, 2003. The expiration
date is October 31, 2004. Program Number 018-999-03-107-H01.
This activity should take approximately
1 hour to complete. The participant should, in order, read the objectives,
read the article, answer the 10-question multiple-choice post-test,
and complete the evaluation. The evaluation form provides each participant
with the opportunity to comment on the quality of the instructional
process, the perception of enhanced professional effectiveness, the
perception of commercial bias, and his or her views on future educational
needs. To receive credit for this activity, follow the instructions
provided on the answer sheet. This credit will be valid through October
31, 2004. No credit will be given after this date.
regarding the content of this activity, contact Dannemiller Memorial
Educational Foundation, accredited provider for this CME/CE activity,
at firstname.lastname@example.org. For technical
assistance, please contact email@example.com.
Director, Early Stage Breast Cancer Program
Cancer Research Network Inc.
Vogel, MD, FACP
Sylvester Comprehensive Cancer Center
University of Miami School of Medicine
Joshua F. Kilbridge
It is the policy of the Dannemiller Memorial
Educational Foundation that faculty participating in a continuing
medical education activity disclose to participants any significant
financial interest or other relationship (1) with the manufacturer(s)
of any commercial product(s) and/or provider(s) of commercial services
discussed in an educational presentation, and (2) with any commercial
supporters of the activity.
Dr. Tan-Chiu reports no such relationships. Dr. Vogel
discloses that he serves on the speakers bureaus of Amgen, AstraZeneca,
Aventis, Biomira, Bristol-Myers Squibb, Celgene, Eli Lilly and Company,
Genentech, GlaxoSmithKline, Novartis, Ortho Biotech, Pfizer, Pierre
Fabre, and Roche; he is a consultant for AstraZeneca, Aventis, BCIRG,
Biomira, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Ortho Biotech,
and Pfizer; and he has received research support from Amgen, Aventis,
BCIRG, Biomira, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline,
Novartis, NSABP, Ortho Biotech, Pfizer, and Roche.
This monograph was drafted by Joshua F. Kilbridge, who has
no relationships to disclose. The content of this activity was controlled
and approved by the faculty.
OF UNLABELED USE
activity contains discussion of published and/or investigational uses
of cyclophosphamide, docetaxel, doxorubicin, fluorouracil, paclitaxel,
and tamoxifen; some uses of these agents have not been approved by
the FDA. Please refer to the official prescribing information for
each product for discussion of approved indications, contraindications,
(v5.5 or greater) or Netscape
(v7.02 or greater)
Windows 98, SE or above; OR Mac OS 10.2; 800 x 600 minimum monitor
resolution (1024 x 768 recommended)
Jointly sponsored by the Dannemiller Memorial Educational
Foundation and the McMahon Publishing Group.
Sponsored for pharmacists by Purdue University.
To access the Dannemiller site
please click on the logo.
activity is supported through an unrestricted educational grant from
Licensed in the U.S. Click Here
Not Licensed in the U.S. and all Others Click Here